The monopolistic market shaken by approval of a domestic tetravalent flu vaccine

Green Cross, a domestic vaccine manufacturer, will enter the tetravalent influenza vaccine market, which was expected to be led by GSK during this season(2015-2016).

Green Cross has started to conduct a Phase 3 clinical study last year and applied for approval from the Ministry of Food and Drug Safety this April. With speed of the usual process, it was expected to acquire an approval in the be...